ADCT
ADC Therapeutics SA
NYSEUSDEQUITY
Healthcare
DELAYED
Last price
0.99
▲ 0.03 (3.11%)
MARKET · —
Price
Open
0.96
Prev close
0.96
Day high
1.00
Day low
0.97
Volume
938.29K
Market cap
$127.23M
P/E (TTM)
—
52W range
0.78 – 4.98
Trailing performance
Returnvs SPY
1W
-1.29%
+0.1%
1M
-18.28%
-22.0%
3M
-70.68%
-73.8%
6M
-75.68%
-86.7%
YTD
-71.76%
-84.0%
1Y
-67.94%
-87.9%
3Y
-31.24%
-105.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$127.23M
Enterprise value$346.32M
Revenue (TTM)$79.58M
Gross profit$-9.23M
EBITDA$-93.71M
Net income$-96.91M
EPS (TTM)$-0.58
Free cash flow$-68.12M
Total cash$219.11M
Total debt$438.19M
Book value / share$-1.79
Shares outstanding127.67M
Float88.56M
Short % of float4.72%
Dividend yield—
Beta (5Y)1.84
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.67
PEG ratio—
Price / sales—
Price / book—
EV / revenue4.35
EV / EBITDA-3.70
Gross margin-11.59%
Operating margin-118.14%
Profit margin-121.77%
Return on equity—
Return on assets-19.57%
Debt / equity—
Current ratio3.03
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $81.36M | $70.84M | $69.56M | $209.91M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$142.62M | -$157.85M | -$240.05M | -$155.80M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$142.62M | -$157.85M | -$240.05M | -$155.80M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.22 | -0.11 | +49.1% |
| Mar 2026 | -0.20 | -0.21 | -4.1% |
| Dec 2025 | -0.27 | -0.04 | +85.1% |
| Sep 2025 | -0.36 | -0.30 | +17.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.21 | 5 | $18.86M | +14.8% |
| Next quarter | -0.20 | 5 | $22.07M | -4.3% |
| Current year | -0.76 | 4 | $80.65M | -0.9% |
| Next year | -0.68 | 4 | $101.96M | +26.4% |
Analyst targets & ownership
Mean target$3.33
High target$5.00
Low target$2.00
Implied upside236.70%
Analyst count3
ConsensusBUY
Strong buy / Buy0 / 3
Hold2
Sell / Strong sell0 / 0
Held by insiders14.42%
Held by institutions67.54%
Institutions holding152
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
-4.25M
Net selling
Buy transactions
11
1.63M shares
Sell transactions
1
5.88M shares
Net transactions
+12
Buys less sells
Sell : buy shares
3.6 : 1
Mixed
Insider-held shares
18.41M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 30, 26 | GRAHAM PETER J Officer |
STOCK | 221.10K | $0 | Direct |
| Jun 30, 26 | CARMONA JOSE Chief Financial Officer |
STOCK | 203.70K | $0 | Direct |
| Jun 30, 26 | MALLIK AMEET Chief Executive Officer |
STOCK | 675.00K | $0 | Direct |
| Jun 30, 26 | ZAKI MOHAMED Officer |
STOCK | 213.90K | $0 | Direct |
| Jun 1, 26 | COUGHLIN TIMOTHY P Director |
STOCK | 45.00K | $0 | Direct |
| Jun 1, 26 | SQUARER RON R Director |
STOCK | 45.00K | $0 | Direct |
| Jun 1, 26 | BIZZARI JEAN-PIERRE Director |
STOCK | 45.00K | $0 | Direct |
| Jun 1, 26 | SANDOR VICTOR Director |
STOCK | 45.00K | $0 | Direct |
| Jun 1, 26 | AZELBY ROBERT W Director |
STOCK | 45.00K | $0 | Direct |
| Jun 1, 26 | MONGES VIVIANE Director |
STOCK | 45.00K | $0 | Direct |
| Jun 1, 26 | HUG PETER Director |
STOCK | 45.00K | $0 | Direct |
| Apr 2, 26 | REDMILE GROUP, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
SELL | 5.88M | $19.64M | Indirect |
| Feb 13, 26 | GRAHAM PETER J Officer |
STOCK | 294.80K | $1.18M | Direct |
| Feb 13, 26 | CARMONA JOSE Chief Financial Officer |
STOCK | 271.60K | $1.08M | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BIZZARI JEAN-PIERRE |
Director | 139.30K | Stock Award(Grant) |
CARMONA JOSE |
Chief Financial Officer | 938.08K | Stock Award(Grant) |
GRAHAM PETER J |
Officer | 841.64K | Stock Award(Grant) |
HUG PETER |
Director | 263.34K | Stock Award(Grant) |
KALLEBO LISA MICHELLE |
Officer | 128.22K | Stock Award(Grant) |
MALLIK AMEET |
Chief Executive Officer | 2.12M | Stock Award(Grant) |
MONGES VIVIANE |
Director | 186.45K | Stock Award(Grant) |
REDMILE GROUP, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
SANDOR VICTOR |
Director | 140.69K | Stock Award(Grant) |
ZAKI MOHAMED |
Officer | 896.32K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
1.07
-7.71% from price
SMA 20
1.09
-8.18% from price
SMA 50
1.14
-12.46% from price
SMA 100
2.28
-56.53% from price
SMA 200
3.11
-67.91% from price
EMA 12
1.06
-6.57% from price
EMA 26
1.14
-12.79% from price
EMA 50
1.40
-29.28% from price
RSI (14)
39.1
Neutral
MACD (12,26,9)
-0.08
Hist 0.00
ATR (14)
0.09
9.25% of price
Realised vol 30D
77.9%
Annualised
Bollinger upper
1.21
20, 2σ
Bollinger lower
0.96
20, 2σ
50 / 200 cross
Death
1.14 vs 3.11
Trend bias
Below 200
-67.91%
Risk profile
Beta vs SPY
1.34
More volatile than market
Correlation to SPY
0.19
Largely independent
Realised vol 30D
77.9%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-80.3%
Peak to trough
Max drawdown 5Y
-98.5%
Peak to trough
ATR 14
0.09
9.25% of price
Beta (reported)
1.84
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.00
Call-heavy session
Put / call open interest
0.03
Positioning, not flow
Max pain
2.50
+150.9% from spot
ATM implied vol
393.8%
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
6
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
2.50
19 contracts
Heaviest put OI
2.50
1 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
ADC Therapeutics (ADCT) Q2 2026 Earnings Call Transcript
Motley Fool · 2d ago
ADC Therapeutics (ADCT) Stock Fair Value Falls After LOTIS 5 Reshapes Zynlonta Outlook
Simply Wall St. · 6d ago
ADC Therapeutics Balances LOTIS-5 Regulatory Risk With LOTIS-7 Opportunity, RBC Says
MT Newswires · 8d ago
ADC Therapeutics S.A. Q2 2026 Earnings Call Summary
Moby · 9d ago
ADC Therapeutics SA (ADCT) (Q2 2026) Earnings Call Highlights: Navigating Regulatory Hurdles ...
GuruFocus.com · 9d ago
ADC Therapeutics Q2 Earnings Call Highlights
MarketBeat · 9d ago
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
Zacks · 9d ago
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
PR Newswire · 9d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.